engleski

Antimicrobial susceptibility and beta-lactamase production of selected Gram-negative bacilli from two Croatian hospitals : MYSTIC study results

Meropenem Yearly Susceptibility test Information Collection (MYSTIC) Programme is a global, longitudinal resistance surveillance network that monitors the activity of meropenem and compares its activity with other broad-spectrum antimicrobial agents. We now report the results collected over a six year period (2002-2007) for the antimicrobial efficacy of meropenem compared to other broad-spectrum agents within the selective Gram-negative pathogen groups from the two Croatian Hospitals located in different geographical regions of Croatia. In two Croatian hospitals total of 1, 510 Gram-negative pathogens were tested. The minimum-inhibitory concentrations (MIC) were determined by broth microdilution method according to CLSI. There was no resistance to either imipenem or meropenem observed for E. coli, K. pneumoniae and P. mirabilis in both medical centers. High resistance rates of K. pneumoniae to ceftazidime (18%), cefepime (17%) and gentamicin (39%) are raising concern. High rates of resistance (%)were observed to most of the tested antibiotics for A. baumannii. 19.2 % of P. aeruginosa strains were resistant to imipenem and 12.9% to meropenem, 69% to gentamicin and 38% to ciprofloxacin. According to our results meropenem remains an appropriate antibiotic for the treatment of severe infections caused by Gram- negative bacteria These data provide evidence that despite the continued use of meropenem, carbapenem resistance is not increasing among those species tested, except for A. baumannii suggesting that clinicians can still administer carbapenems as reliable and effective choice in managing serious nosocomial infections at these two Croatian hospitals.

MYSTIC; meropenem; imipenem; resistance mechanisms

nije evidentirano